XORTX Therapeutics Inc (XRTX)

US · Healthcare · Biotechnology

$2.16+1.41%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-808,472

Profit YoY

-15.7%

EPS

$-0.58

Market cap

$3.7M

Forward P/E

1.0

P/B

2.87

Book value

$0.92

EPS (TTM)

$-2.45

52-week high

$7.05

52-week low

$1.73

50-day MA

$2.15

200-day MA

$2.54

Beta

0.08

Analysts rate XORTX Therapeutics Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $14.04.

Insiders

7.83%

Institutions

2.13%

Fund	Stake
Kingsview Wealth Management, LLC	0.17%
Hartland & Co	0.00%
DRW Securities, LLC	0.00%
Royal Bank of Canada	0.00%
Baader Bank INC	0.00%
TWO SIGMA SECURITIES, LLC	0.00%
UBS Group AG	0.00%

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for XORTX Therapeutics Inc — free to start.

Data updated 2026-08-05.